PML body meets telomere: The beginning of an ALTernate ending?

Nucleus (United States)

Volumn 3, Issue 3, 2012, Pages

  Chung, Inn ^a   Osterwald, Sarah ^a   Deeg, Katharina I ^a   Rippe, Karsten ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

ALT; ALT associated PML bodies; Alternative lengthening of telomeres; Cellular immortalization; DNA recombination; DNA repair; Promyelocytic leukemia nuclear bodies

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN;

ALTERNATIVE LENGTHENING OF TELOMERE; CANCER CELL; DNA RECOMBINATION; DNA REPAIR; HUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN STRUCTURE; REVIEW; TELOMERE; TELOMERE HOMEOSTASIS;

EID: 84863824454     PISSN: 19491034     EISSN: 19491042     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88:657-66; PMID:9054505; http://dx.doi. org/10.1016/S0092-8674(00)81908-X.
2. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97:503-14; PMID:10338214; http://dx.doi.org/10.1016/S0092-8674(00)80760-6.
3. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42:301-34; PMID:18680434; http://dx.doi.org/10.1146/annurev. genet.41.110306.130350.
4. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19:2100-10; PMID:16166375; http://dx.doi. org/10.1101/gad.1346005.
5. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345:458-60; PMID:2342578; http://dx.doi. org/10.1038/345458a0.
6. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426:194-8; PMID:14608368; http://dx.doi.org/10.1038/nature02118.
7. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585-621; http://dx.doi.org/10.1016/0014-4827(61)90192-6.
8. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130:223-33; PMID:17662938; http://dx.doi.org/10.1016/j. cell.2007.07.003.
9. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-91; PMID:9282118; http://dx.doi.org/10.1016/S0959-8049(97)00062-2.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5; PMID:7605428; http://dx.doi.org/10.1126/science.7605428.
11. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett 2010; 584:3800-11; PMID:20542034; http://dx.doi.org/10.1016/j.febslet.2010.06.009.
12. Johnson JE, Broccoli D. Telomere maintenance in sarcomas. Curr Opin Oncol 2007; 19:377-82; PMID:17545803; http://dx.doi.org/10.1097/CCO.0b013e3281214423.
13. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179:1608-15; PMID:21888887; http://dx.doi.org/10.1016/j.ajpath.2011.06.018.
14. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21:598-610; PMID:11850785; http://dx.doi.org/10.1038/sj.onc.1205058.
15. Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 2004; 24:9948-57; PMID:15509797; http://dx.doi.org/10.1128/MCB.24.22.9948-57.2004.
16. Ogino H, Nakabayashi K, Suzuki M, Takahashi E, Fujii M, Suzuki T, et al. Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. Biochem Biophys Res Commun 1998; 248:223-7; PMID:9675117; http://dx.doi. org/10.1006/bbrc.1998.8875.
17. Tokutake Y, Matsumoto T, Watanabe T, Maeda S, Tahara H, Sakamoto S, et al. Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines. Biochem Biophys Res Commun 1998; 247:765-72; PMID:9647768; http://dx.doi. org/10.1006/bbrc.1998.8876.
18. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11:319-30; PMID:20351727; http://dx.doi.org/10.1038/nrg2763.
19. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, et al. DNA C-circles are specific and quantifiable markers of alternative-lengtheningof-telomeres activity. Nat Biotechnol 2009; 27:1181-5; PMID:19935656; http://dx.doi.org/10.1038/nbt.1587.
20. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 2004; 64:3444-51; PMID:15150096; http://dx.doi.org/10.1158/0008-5472.CAN-04-0323.
21. Londoño-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004; 64:2324-7; PMID:15059879; http://dx.doi.org/10.1158/0008-5472.CAN-03-4035.
22. Lang M, Jegou T, Chung I, Richter K, Münch S, Udvarhelyi A, et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 2010; 123:392-400; PMID:20130140; http://dx.doi. org/10.1242/jcs.053496.
23. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59:4175-9; PMID:10485449.
24. Nabetani A, Ishikawa F. Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. J Biochem 2011; 149:5-14; PMID:20937668; http://dx.doi. org/10.1093/jb/mvq119.
25. Durant ST. Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer 2012; 3:67-82; PMID:22315652; http://dx.doi.org/10.7150/jca.3965.
26. Cerone MA, Autexier C, Londoño-Vallejo JA, Bacchetti S. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene 2005; 24:7893-901; PMID:16116482; http://dx.doi.org/10.1038/sj.onc.1208934.
27. Fasching CL, Bower K, Reddel RR. Telomeraseindependent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 2005; 65:2722-9; PMID:15805271; http://dx.doi. org/10.1158/0008-5472.CAN-04-2881.
28. Marciniak RA, Cavazos D, Montellano R, Chen Q, Guarente L, Johnson FB. A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res 2005; 65:2730-7; PMID:15805272; http://dx.doi.org/10.1158/0008-5472.CAN-04-2888.
29. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13:1073-83; PMID:8131741.
30. Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, et al. Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep 2006; 7:397-403; PMID:16415788.
31. Boisvert FM, Hendzel MJ, Bazett-Jones DP. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol 2000; 148:283-92; PMID:10648561; http://dx.doi. org/10.1083/jcb.148.2.283.
32. Lallemand-Breitenbach V, de Thé H. PML nuclear bodies. Cold Spring Harb Perspect Biol 2010; 2:661; PMID:20452955; http://dx.doi.org/10.1101/cshperspect. a000661.
33. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, NeffN, Kamitani T, et al. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 1999; 147:221-34; PMID:10525530; http://dx.doi.org/10.1083/jcb.147.2.221.
34. Zhong S, Müller S, Ronchetti S, Freemont PS, Dejean A, PandolfiPP. Role of SUMO-1-modified PML in nuclear body formation. Blood 2000; 95:2748-52; PMID:10779416.
35. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, et al. Dynamics of component exchange at PML nuclear bodies. J Cell Sci 2008; 121:2731-43; PMID:18664490; http://dx.doi. org/10.1242/jcs.031922.
36. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. Specification of SUMO1-and SUMO2-interacting motifs. J Biol Chem 2006; 281:16117-27; PMID:16524884; http://dx.doi.org/10.1074/jbc. M512757200.
37. Houlard M, Berlivet S, Probst AV, Quivy JP, Héry P, Almouzni G, et al. CAF-1 is essential for heterochromatin organization in pluripotent embryonic cells. PLoS Genet 2006; 2:181; PMID:17083276; http://dx.doi.org/10.1371/journal.pgen.0020181.
38. Ayaydin F, Dasso M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 2004; 15:5208-18; PMID:15456902; http://dx.doi. org/10.1091/mbc.E04-07-0589.
39. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000; 275:6252-8; PMID:10692421; http://dx.doi.org/10.1074/jbc.275.9.6252.
40. Van Damme E, Laukens K, Dang TH, Van Ostade X. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci 2010; 6:51-67; PMID:20087442; http://dx.doi.org/10.7150/ijbs.6.51.
41. Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH, et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics 2008; 7:132-44; PMID:17938407; http://dx.doi.org/10.1074/mcp. M700173-MCP200.
42. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005; 9:769-79; PMID:16326389; http://dx.doi.org/10.1016/j.devcel.2005.10.007.
43. Quimby BB, Yong-Gonzalez V, Anan T, Strunnikov AV, Dasso M. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene 2006; 25:2999-3005; PMID:16501610; http://dx.doi. org/10.1038/sj.onc.1209335.
44. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999; 112:381-93; PMID:9885291.
45. Sternsdorf T, Jensen K, Will H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 1997; 139:1621-34; PMID:9412458; http://dx.doi. org/10.1083/jcb.139.7.1621.
46. Shen TH, Lin HK, Scaglioni PP, Yung TM, PandolfiPP. The mechanisms of PML-nuclear body formation. Mol Cell 2006; 24:331-9; PMID:17081985; http://dx.doi.org/10.1016/j.molcel.2006.09.013.
47. Sternsdorf T, Jensen K, Reich B, Will H. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization and modification by small ubiquitin-like modifiers. J Biol Chem 1999; 274:12555-66; PMID:10212234; http://dx.doi.org/10.1074/jbc.274.18.12555.
48. Dellaire G, Eskiw CH, Dehghani H, Ching RW, Bazett-Jones DP. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci 2006; 119:1034-42; PMID:16492707; http://dx.doi.org/10.1242/jcs.02817.
49. Eladad S, Ye TZ, Hu P, Leversha M, Beresten S, Matunis MJ, et al. Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet 2005; 14:1351-65; PMID:15829507; http://dx.doi. org/10.1093/hmg/ddi145.
50. Takahashi H, Hatakeyama S, Saitoh H, Nakayama KI. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J Biol Chem 2005; 280:5611-21; PMID:15569683; http://dx.doi.org/10.1074/jbc. M408130200.
51. Renner F, Moreno R, Schmitz ML. SUMOylationdependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damagetriggered cell death. Mol Cell 2010; 37:503-15; PMID:20188669; http://dx.doi.org/10.1016/j.molcel.2010.01.018.
52. Nagai S, Davoodi N, Gasser SM. Nuclear organization in genome stability: SUMO connections. Cell Res 2011; 21:474-85; PMID:21321608; http://dx.doi. org/10.1038/cr.2011.31.
53. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11:217-25; PMID:15671549.
54. Jiang WQ, Zhong ZH, Nguyen A, Henson JD, Toouli CD, Braithwaite AW, et al. Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J Cell Biol 2009; 185:797-810; PMID:19468068; http://dx.doi. org/10.1083/jcb.200810084.
55. Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFarlane M, et al. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am J Pathol 2010; 177:2694-700; PMID:21037079; http://dx.doi. org/10.2353/ajpath.2010.100468.
56. Osterwald S, Wörz S, Reymann J, Sieckmann F, Rohr K, Erfle H, et al. A three-dimensional colocalization RNA interference screening platform to elucidate the alternative lengthening of telomeres pathway. Biotechnol J 2012; 7:103-16; PMID:21648092; http://dx.doi.org/10.1002/biot.201000474.
57. Nabetani A, Yokoyama O, Ishikawa F. Localization of hRad9, hHus1, hRad1 and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J Biol Chem 2004; 279:25849-57; PMID:15075340; http://dx.doi.org/10.1074/jbc.M312652200.
58. Stavropoulos DJ, Bradshaw PS, Li X, Pasic I, Truong K, Ikura M, et al. The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum Mol Genet 2002; 11:3135-44; PMID:12444098; http://dx.doi. org/10.1093/hmg/11.25.3135.
59. Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol 2007; 14:581-90; PMID:17589526; http://dx.doi. org/10.1038/nsmb1259.
60. Chung I, Leonhardt H, Rippe K. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation. J Cell Sci 2011; 124:3603-18; PMID:22045732; http://dx.doi.org/10.1242/jcs.084681.
61. Zeng S, Xiang T, Pandita TK, Gonzalez-Suarez I, Gonzalo S, Harris CC, et al. Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol 2009; 11:616-23; PMID:19363487; http://dx.doi. org/10.1038/ncb1867.
62. Wu G, Jiang X, Lee WH, Chen PL. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 2003; 63:2589-95; PMID:12750284.
63. Chen YC, Kappel C, Beaudouin J, Eils R, Spector DL. Live cell dynamics of promyelocytic leukemia nuclear bodies upon entry into and exit from mitosis. Mol Biol Cell 2008; 19:3147-62; PMID:18480407; http://dx.doi.org/10.1091/mbc.E08-01-0035.
64. Görisch SM, Wachsmuth M, Ittrich C, Bacher CP, Rippe K, Lichter P. Nuclear body movement is determined by chromatin accessibility and dynamics. Proc Natl Acad Sci USA 2004; 101:13221-6; PMID:15331777; http://dx.doi.org/10.1073/pnas.0402958101.
65. Jegou T, Chung I, Heuvelman G, Wachsmuth M, Görisch SM, Greulich-Bode KM, et al. Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line. Mol Biol Cell 2009; 20:2070-82; PMID:19211845; http://dx.doi. org/10.1091/mbc.E08-02-0108.
66. Muratani M, Gerlich D, Janicki SM, Gebhard M, Eils R, Spector DL. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat Cell Biol 2002; 4:106-10; PMID:11753375; http://dx.doi.org/10.1038/ncb740.
67. Wachsmuth M, Caudron-Herger M, Rippe K. Genome organization: balancing stability and plasticity. Biochim Biophys Acta 2008; 1783:2061-79; PMID:18722483; http://dx.doi.org/10.1016/j.bbamcr.2008.07.022.
68. Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ, et al. Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 2003; 22:6631-41; PMID:14657034; http://dx.doi. org/10.1093/emboj/cdg633.
69. Belmont AS, Li G, Sudlow G, Robinett C. Visualization of large-scale chromatin structure and dynamics using the lac operator/lac repressor reporter system. Methods Cell Biol 1999; 58:203-22; PMID:9891383; http://dx.doi.org/10.1016/S0091-679X(08)61957-3.
70. Belmont AS, Straight AF. In vivo visualization of chromosomes using lac operator-repressor binding. Trends Cell Biol 1998; 8:121-4; PMID:9695822; http://dx.doi.org/10.1016/S0962-8924(97)01211-7.
71. Robinett CC, Straight A, Li G, Willhelm C, Sudlow G, Murray A, et al. In vivo localization of DNA sequences and visualization of large-scale chromatin organization using lac operator/repressor recognition. J Cell Biol 1996; 135:1685-700; PMID:8991083; http://dx.doi. org/10.1083/jcb.135.6.1685.
72. Dimitrova N, Chen YC, Spector DL, de Lange T. 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nature 2008; 456:524-8; PMID:18931659; http://dx.doi. org/10.1038/nature07433.
73. Krajewski WA, Nakamura T, Mazo A, Canaani E. A motif within SET-domain proteins binds single-stranded nucleic acids and transcribed and supercoiled DNAs and can interfere with assembly of nucleosomes. Mol Cell Biol 2005; 25:1891-9; PMID:15713643; http://dx.doi.org/10.1128/MCB.25.5.1891-9.2005.
74. Brouwer AK, Schimmel J, Wiegant JC, Vertegaal AC, Tanke HJ, Dirks RW. Telomeric DNA mediates de novo PML body formation. Mol Biol Cell 2009; 20:4804-15; PMID:19793919; http://dx.doi. org/10.1091/mbc.E09-04-0309.
75. Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007; 89:819-30; PMID:17343971; http://dx.doi. org/10.1016/j.biochi.2007.01.004.
76. Luciani JJ, Depetris D, Usson Y, Metzler-Guillemain C, Mignon-Ravix C, Mitchell MJ, et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J Cell Sci 2006; 119:2518-31; PMID:16735446; http://dx.doi.org/10.1242/jcs.02965.
77. Benetti R, Gonzalo S, Jaco I, Schotta G, Klatt P, Jenuwein T, et al. Suv4-20 h deficiency results in telomere elongation and derepression of telomere recombination. J Cell Biol 2007; 178:925-36; PMID:17846168; http://dx.doi.org/10.1083/jcb.200703081.
78. Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Estelle rM, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol 2006; 8:416-24; PMID:16565708; http://dx.doi.org/10.1038/ncb1386.
79. Benetti R, García-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet 2007; 39:243-50; PMID:17237781; http://dx.doi.org/10.1038/ng1952.
80. Prowse KR, Greider CW. Developmental and tissuespecific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995; 92:4818-22; PMID:7761406; http://dx.doi.org/10.1073/pnas.92.11.4818.
81. Greenberg RA, Allsopp RC, Chin L, Morin GB, DePinho RA. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 1998; 16:1723-30; PMID:9582020; http://dx.doi.org/10.1038/sj.onc.1201933.
82. Jiang WQ, Nguyen A, Cao Y, Chang AC, Reddel RR. HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a. PLoS One 2011; 6:17036; PMID:21347226; http://dx.doi.org/10.1371/journal. pone.0017036.
83. Fasching CL, Neumann AA, Muntoni A, Yeager TR, Reddel RR. DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res 2007; 67:7072-7; PMID:17652140; http://dx.doi.org/10.1158/0008-5472.CAN-07-1556.
84. Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londoño-Vallejo A. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proc Natl Acad Sci USA 2009; 106:15726-31; PMID:19717459; http://dx.doi.org/10.1073/pnas.0907689106.
85. Wu G, Lee WH, Chen PL. NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 2000; 275:30618-22; PMID:10913111; http://dx.doi.org/10.1074/jbc. C000390200.
86. Nagele RG, Velasco AQ, Anderson WJ, McMahon DJ, Thomson Z, Fazekas J, et al. Telomere associations in interphase nuclei: possible role in maintenance of interphase chromosome topology. J Cell Sci 2001; 114:377-88; PMID:11148139.
87. Costa A, Daidone MG, Daprai L, Villa R, Cantù S, Pilotti S, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006; 66:8918-24; PMID:16951210; http://dx.doi.org/10.1158/0008-5472.CAN-06-0273.
88. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001; 21:3862-75; PMID:11359895; http://dx.doi.org/10.1128/MCB.21.12.3862-75.2001.
89. Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol 2005; 25:2708-21; PMID:15767676; http://dx.doi.org/10.1128/MCB.25.7.2708-21.2005.
90. Hancock R. Internal organisation of the nucleus: assembly of compartments by macromolecular crowding and the nuclear matrix model. Biol Cell 2004; 96:595-601; PMID:15519694; http://dx.doi. org/10.1016/j.biolcel.2004.05.003.
91. Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W, et al. PML is required for homeodomaininteracting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 2003; 63:4310-4; PMID:12907596.
92. Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev 2008; 129:99-108; PMID:18215414; http://dx.doi. org/10.1016/j.mad.2007.11.006.
93. Royle NJ, Foxon J, Jeyapalan JN, Mendez-Bermudez A, Novo CL, Williams J, et al. Telomere length maintenance-an ALTernative mechanism. Cytogenet Genome Res 2008; 122:281-91; PMID:19188697; http://dx.doi.org/10.1159/000167814.
94. Tarsounas M, West SC. Recombination at mammalian telomeres: an alternative mechanism for telomere protection and elongation. Cell Cycle 2005; 4:672-4; PMID:15846103; http://dx.doi.org/10.4161/cc.4.5.1689.
95. Slatter TL, Tan X, Yuen YC, Gunningham S, Ma SS, Daly E, et al. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Pathol 2012; 226:509-18; PMID:22250043; http://dx.doi.org/10.1002/path.2981.
96. Perrem K, Bryan TM, Englezou A, Hackl T, Moy EL, Reddel RR. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene 1999; 18:3383-90; PMID:10362359; http://dx.doi.org/10.1038/sj.onc.1202752.
97. Ishii Y, Tsuyama N, Maeda S, Tahara H, Ide T. Telomerase activity in hybrids between telomerasenegative and telomerase-positive immortal human cells is repressed in the different complementation groups but not in the same complementation group of immortality. Mech Ageing Dev 1999; 110:175-93; PMID:10576247; http://dx.doi.org/10.1016/S0047-6374(99)00054-8.
98. Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, et al. Association of mutant Tp53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006; 66:6473-6; PMID:16818615; http://dx.doi. org/10.1158/0008-5472.CAN-06-0910.
99. Stagno D'Alcontres M, Mendez-Bermudez A, Foxon JL, Royle NJ, Salomoni P. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. J Cell Biol 2007; 179:855-67; PMID:18056407; http://dx.doi.org/10.1083/jcb.200703020.
100. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997; 14:1847-57; PMID:9150391; http://dx.doi. org/10.1038/sj.onc.1201143.
101. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995; 15:4745-53; PMID:7651392.
102. Razak ZR, Varkonyi RJ, Kulp-McEliece M, Caslini C, Testa JR, Murphy ME, et al. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol 2004; 24:5967-77; PMID:15199150; http://dx.doi.org/10.1128/MCB.24.13.5967-77.2004.
103. Cesare AJ, Kaul Z, Cohen SB, Napier CE, Pickett HA, Neumann AA, et al. Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol 2009; 16:1244-51; PMID:19935685; http://dx.doi.org/10.1038/nsmb.1725.
104. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333:425; PMID:21719641; http://dx.doi.org/10.1126/science.1207313.
105. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, PfaffE, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-31; PMID:22286061; http://dx.doi.org/10.1038/nature10833.
106. Xue Y, Gibbons R, Yan Z, Yang D, McDowell TL, Sechi S, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci USA 2003; 100:10635-40; PMID:12953102; http://dx.doi.org/10.1073/pnas.1937626100.
107. Elsaesser SJ, Allis CD. HIRA and Daxx constitute two independent histone H3.3-containing predeposition complexes. Cold Spring Harb Symp Quant Biol 2010; 75:27-34; PMID:21047901; http://dx.doi. org/10.1101/sqb.2010.75.008.
108. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA 2010; 107:14075-80; PMID:20651253; http://dx.doi.org/10.1073/pnas.1008850107.
109. Law MJ, Lower KM, Voon HPJ, Hughes JR, Garrick D, Viprakasit V, et al. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell 2010; 143:367-78; PMID:21029860; http://dx.doi.org/10.1016/j. cell.2010.09.023.
110. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010; 140:678-91; PMID:20211137; http://dx.doi.org/10.1016/j.cell.2010.01.003.
111. Ng LJ, Cropley JE, Pickett HA, Reddel RR, Suter CM. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res 2009; 37:1152-9; PMID:19129228; http://dx.doi. org/10.1093/nar/gkn1030.
112. Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity and Advanced Clinical Grade. Transl Oncol 2012; 5:56-65; PMID:22348177.
113. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004; 119:355-68; PMID:15507207; http://dx.doi.org/10.1016/j. cell.2004.10.011.
114. Fairall L, Chapman L, Moss H, de Lange T, Rhodes D. Structure of the TRFH dimerization domain of the human telomeric proteins TRF1 and TRF2. Mol Cell 2001; 8:351-61; PMID:11545737; http://dx.doi. org/10.1016/S1097-2765(01)00321-5.
115. Muntoni A, Neumann AA, Hills M, Reddel RR. Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum Mol Genet 2009; 18:1017-27; PMID:19095716; http://dx.doi.org/10.1093/hmg/ddn436.
116. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000; 26:447-50; PMID:11101843; http://dx.doi.org/10.1038/82586.
117. Pickett HA, Henson JD, Au AY, Neumann AA, Reddel RR. Normal mammalian cells negatively regulate telomere length by telomere trimming. Hum Mol Genet 2011; 20:4684-92; PMID:21903669; http://dx.doi. org/10.1093/hmg/ddr402.
118. Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR. Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J 2009; 28:799-809; PMID:19214183; http://dx.doi. org/10.1038/emboj.2009.42.
119. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361:836-8; PMID:12642053; http://dx.doi.org/10.1016/S0140-6736(03)12681-5.
120. Brachner A, Sasgary S, Pirker C, Rodgarkia C, Mikula M, Mikulits W, et al. Telomerase-and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res 2006; 66:3584-92; PMID:16585183; http://dx.doi. org/10.1158/0008-5472.CAN-05-2839.
121. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2008; 98:1467-74; PMID:18414473; http://dx.doi.org/10.1038/sj.bjc.6604328.
122. Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010; 10:254; PMID:20525266; http://dx.doi. org/10.1186/1471-2407-10-254.
123. Onitake Y, Hiyama E, Kamei N, Yamaoka H, Sueda T, Hiyama K. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres. J Pediatr Surg 2009; 44:2258-66; PMID:20006006; http://dx.doi.org/10.1016/j.jpedsurg.2009.07.046.
124. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, 2nd, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008; 10:112-20; PMID:18287341; http://dx.doi. org/10.1215/15228517-2007-052.
125. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70:9494-504; PMID:21062983; http://dx.doi.org/10.1158/0008-5472.CAN-10-0233.
126. Corey DR. Telomerase inhibition, oligonucleotides and clinical trials. Oncogene 2002; 21:631-7; PMID:11850789; http://dx.doi.org/10.1038/sj.onc.1205063.
127. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167-79; PMID:18256617; http://dx.doi.org/10.1038/nrc2275.
128. Villa R, Folini M, Lualdi S, Veronese S, Daidone MG, Zaffaroni N. Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Lett 2000; 473:241-8; PMID:10812083; http://dx.doi.org/10.1016/S0014-5793(00)01540-4.
129. Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer 2005; 41:971-9; PMID:15862745; http://dx.doi.org/10.1016/j.ejca.2004.11.024.
130. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, JaskelioffM, et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012; 148:651-63; PMID:22341440; http://dx.doi. org/10.1016/j.cell.2011.12.028.
131. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 2001; 10:1945-52; PMID:11555631; http://dx.doi. org/10.1093/hmg/10.18.1945.